Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Organon & Co.

OGNNYSE
Healthcare
Drug Manufacturers - General
$7.90
$-0.20(-2.41%)
U.S. Market opens in 17h 26m

Organon & Co. (OGN) Stock Overview

Explore Organon & Co.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2.1B
P/E Ratio11.28
EPS (TTM)$0.72
ROE0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$7.36
3 Months$5.96
1 Year Target$0.00

OGN Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Organon & Co. (OGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 52.18, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 11.28 and a market capitalization of 2.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
7.71%
5-Day Change
15.38%
1-Month Change
-14.38%
3-Month Change
13.60%
6-Month Change
-13.55%
Year-to-Date (YTD) Change
11.88%
1-Year Change
-48.37%
3-Year Change
-70.04%
5-Year Change
-75.64%
All-Time (Max) Change
-75.64%

Contact Information

551 430 6000
30 Hudson Street, Jersey City, NJ, 07302

Company Facts

100,000 Employees
IPO DateMay 14, 2021
CountryUS
Actively Trading

Frequently Asked Questions